These work with it
Lee YK, Kim D, Shin DY, Lee CR, Lee EJ, Kang SW, et al
is supported, in part, by a Banting and Best Diabetes CentreNovo Nordisk Chair in Incretin Biology, a Sinai HealthNovo Nordisk Foundation Fund in Regulatory Peptides, CIHR grants 154321 and 19204 and Diabetes Canada-Canadian Cancer Society grant (OG-3- 24-5819-DD)
Given the increasing prevalence of obesity and its associated comorbidities, a comprehensive evaluation of the impact of semaglutide on these outcomes is crucial for guiding clinical practice
By leveraging technology, patients can receive personalized care plans that include dietary recommendations and exercise regimens tailored to work synergistically with Zepbound, enhancing their chances of achieving sustainable weight loss and improved health outcomes